$LQDA

JEFFS ROGER sold $1.5M of LQDA (indirect holdings)

JEFFS ROGER (Chief Executive Officer) sold 25,000 indirectly-held shares of Liquidia Corp (LQDA) at $61.13 ($1.53M total) on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · JEFFS ROGER
Published May 26, 2026, 10:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralMed
01

Why it matters

The disclosure can influence short-term sentiment and options/flow positioning, but the presence of a 10b5-1 plan generally lowers the probability that the sale signals new adverse fundamentals.

02

Market read

A $1.53M CEO open-market sale under a 10b5-1 plan is more of a sentiment datapoint than a fundamental catalyst for LQDA.

03

What to watch

Check whether there are multiple consecutive insider sales, changes in total insider ownership, or concurrent news (trial/financing) that would make the sale more informative.

Relevance 7/10Timing: Potential short-term sentiment effect around the filing date (2026-05-26) and subsequent tape reaction.

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp, filed on 2026-05-26, covering a sale executed 2026-05-21.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia CEO Jeffs Roger sold 25,000 shares in an open-market transaction worth about $1.53M under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any reaction may fade unless accompanied by other negative company-specific news.

Evidence & confidence

The filing is an SEC Form 4 insider sale with explicit 10b5-1 pre-arrangement, which typically dampens interpretability as a new bearish thesis.

Market effects

Minimal sector read-through; this is company-specific insider liquidity rather than an operational/regulatory update.

No clear regional impact indicated by the filing alone.

No global relevance beyond the issuer’s own trading sentiment.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine diversification/compensation rather than negative expectations.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction; CEO sold 25,000 shares open-market under a 10b5-1 plan.

  • Jeffs Roger

    Chief Executive Officer and director who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient